Authors: CILLA DD WANG T FORBES WP NAKAJIMA K

Citation: Dd. Cilla et al., CHARACTERISTICS OF DYSLIPIDEMIA IN INTERMITTENT CLAUDICATION PATIENTS, Atherosclerosis, 134(1-2), 1997, pp. 344-344

Authors: POSVAR EL RADULOVIC LL CILLA DD WHITFIELD LR SEDMAN AJ

Citation: El. Posvar et al., TOLERANCE AND PHARMACOKINETICS OF SINGLE-DOSE ATORVASTATIN, A POTENT INHIBITOR OF HMG-COA REDUCTASE, IN HEALTHY-SUBJECTS, Journal of clinical pharmacology, 36(8), 1996, pp. 728-731

Authors: CILLA DD GIBSON DM WHITFIELD LY SEDMAN AJ

Citation: Dd. Cilla et al., PHARMACODYNAMIC EFFECTS AND PHARMACOKINETICS OF ATORVASTATIN AFTER ADMINISTRATION TO NORMOCHOLESTEROLEMIC SUBJECTS IN THE MORNING AND EVENING, Journal of clinical pharmacology, 36(7), 1996, pp. 604-609

Authors: SCHAEFER EJ LAMONFAVA S COLE T SPRECHER DL CILLA DD BALAGTAS CC ROWAN JP BLACK DM

Citation: Ej. Schaefer et al., EFFECTS OF REGULAR AND EXTENDED-RELEASE GEMFIBROZIL ON PLASMA-LIPOPROTEINS AND APOLIPOPROTEINS IN HYPERCHOLESTEROLEMIC PATIENTS WITH DECREASED HDL CHOLESTEROL LEVELS, Atherosclerosis, 127(1), 1996, pp. 113-122

Authors: CILLA DD WHITFIELD LR GIBSON DM SEDMAN AJ POSVAR EL

Citation: Dd. Cilla et al., MULTIPLE-DOSE PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF ATORVASTATIN, AN INHIBITOR OF HMG-COA REDUCTASE, IN HEALTHY-SUBJECTS, Clinical pharmacology and therapeutics, 60(6), 1996, pp. 687-695

Authors: RADULOVIC LL CILLA DD POSVAR EL SEDMAN AJ WHITFIELD LR

Citation: Ll. Radulovic et al., EFFECT OF FOOD ON THE BIOAVAILABILITY OF ATORVASTATIN, AN HMG-COA REDUCTASE INHIBITOR, Journal of clinical pharmacology, 35(10), 1995, pp. 990-994